Highly stable super-drugs
In a recent study published in the prestigious Journal Science Translational Medicine, a new, highly stable engineered anti-hemorrhagic molecule is described. This ability is of great importance for coagulation- related diseases, as it could translate into a greater therapeutic window allowing a reduction in the number of injections, with a consequent improvement in the quality of life of the patients treated. The study, conducted by Dr. Alessio Branchini and Prof. Mirko Pinotti of LTTA in collaboration with an international research team with expertise in immunology, biochemistry and coagulation diseases, is reported at the link: An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics . In particular, the drug combines the characteristics of coagulation factor VII, useful for preventing / stopping bleeding, with those of albumin, a protein that naturally circulates in our blood and which is highly stable. The combination of the two characteristics gives the engineered factor, that is the drug, the ability to be effective in the blood for longer time, in comparison to existing treatments.